Ah! Glib gets me every time. Clearly they achieved results needed to excite investors but didn't create a study that was going to create a complete paradigm shift in standard of care/guidelines, although suspect they have definitely 'moved the needle.'
But all of this comes back to a really rigorous RCT! If we had such results, and cost data, we could know exactly how effective Virta is compared to the next best treatment Alas, we don't have this information, which is a big issue
-
-
Has anyone looked at cost effectiveness as it related to CSIRO study? Seems that could give a satisfactory answer with regards to cost savings from med reductions in the low carb arm.
-
I don't think they looked at costs from memory, they used a combination medication score. They also didn't use Virta, I believe their model was less intensive. Also, the cost-benefit of a 0.3 reduction in medication effect score might not be very high
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.